Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Ipratropium Bromide in Peri-Operative COPD

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: ipratropium bromide
Drug: placebo

First Posted Date: 2013-09-17

Last Posted Date: 2016-10-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 192

Registration Number: NCT01943552

Locations: 🇨🇳
244.2514.86002 Boehringer Ingelheim Investigational Site, Tianjin, China
🇨🇳
244.2514.86006 Boehringer Ingelheim Investigational Site, Guangzhou, China
🇨🇳
244.2514.86009 Boehringer Ingelheim Investigational Site, Hangzhou, China

and more 6 locations

Iota-Carrageenan Nasal Spray in Common Cold

Phase 4

Completed

Conditions: Common Cold

Interventions: Device: Placebo
Device: Iota-Carrageenan

First Posted Date: 2013-09-17

Last Posted Date: 2015-04-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 200

Registration Number: NCT01944631

Locations: 🇬🇧
1326.1.44001 Boehringer Ingelheim Investigational Site, Cardiff, United Kingdom

Effect of BI 207127 + Faldaprevir on Blood Levels of Oral Contraceptives Containing Ethinylestradiol and Levonorgestrel

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: faldaprevir
Drug: Microgynon®
Drug: BI 207127

First Posted Date: 2013-09-13

Last Posted Date: 2016-04-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT01941615

Locations: 🇩🇪
1241.31.2 Boehringer Ingelheim Investigational Site, Mannheim, Germany

BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BI 860585
Drug: exemestane
Drug: paclitaxel

First Posted Date: 2013-09-10

Last Posted Date: 2019-01-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 90

Registration Number: NCT01938846

Locations: 🇧🇪
UNIV UZ Gent, Gent, Belgium
🇧🇪
Brussels - UNIV Saint-Luc, Bruxelles, Belgium
🇮🇹
Azienda Ospedaliera di Parma, Parma, Italy

and more 1 locations

Observational Study of Adherence to LABA / LAMA in Chronic Obstructive Pulmonary Disease (COPD)

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium 2x2.5µg tiotropium (equivalent to 2x3.154µg tiotropium bromide monohydrate) Respimat® inhaler and cartridge Solution for inhalation
Drug: Indacterol 300 µg
Drug: Tiotropium 18µg (equivalent to 22.5µg tiotropium bromide monohydrate) HandiHaler® device Inhalation powder, hard capsule
Drug: Indacterol 150 µg

First Posted Date: 2013-09-09

Last Posted Date: 2018-07-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 645

Registration Number: NCT01937390

Locations: 🇩🇪
CTMS MIGRATION CENTER representing all obvious CTMS Dummy Sites, Ingelheim am Rhein, Germany

GLORIA-AF Registry Program (Phase II/III)

Completed

Conditions: Stroke
Atrial Fibrillation

First Posted Date: 2013-09-09

Last Posted Date: 2021-02-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 200

Registration Number: NCT01937377

Locations: 🇨🇭
Kantonsspital St.Gallen, St. Gallen, Switzerland
🇨🇭
CHUV - Centre hospitalier universitaire vaudois, Lausanne, Switzerland
🇨🇭
University Hospital Basel, Basel, Switzerland

and more 2 locations

Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)

Conditions: Carcinoma, Non-Small-Cell Lung

First Posted Date: 2013-08-29

Last Posted Date: 2018-11-14

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT01931306

Locations: 🇰🇷
The Catholic University of Korea, Bucheon St.Mary's Hospital, Bucheon, Korea, Republic of
🇰🇷
Chonnam National University Hwasun Hospital, Jeonnam, Korea, Republic of
🇰🇷
Gachon University Gil Medical Center, Incheon, Korea, Republic of

and more 5 locations

Efficacy and Safety of Ibuprofen and Caffeine in Dental Pain

Phase 3

Completed

Conditions: Tooth Diseases
Pain, Postoperative

Interventions: Drug: ibuprofen + caffeine
Drug: ibuprofen
Drug: placebo
Drug: caffeine

First Posted Date: 2013-08-27

Last Posted Date: 2016-11-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 562

Registration Number: NCT01929031

Locations: 🇺🇸
1335.1.202 Boehringer Ingelheim Investigational Site, Salt Lake City, Utah, United States

Efficacy of Buscopan® in Comparison With 654-II (Anisodamine) in Acute Gastric or Intestinal Pain

Phase 3

Completed

Conditions: Intestinal Diseases

Interventions: Drug: Buscopan® (hyoscine butylbromide)
Drug: 654-II (anisodamine)

First Posted Date: 2013-08-27

Last Posted Date: 2016-03-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 299

Registration Number: NCT01929044

Locations: 🇨🇳
202.848.86013 Boehringer Ingelheim Investigational Site, Beijing, China
🇨🇳
202.848.86020 Boehringer Ingelheim Investigational Site, Changsha, China
🇨🇳
202.848.86007 Boehringer Ingelheim Investigational Site, Chongqing, China

and more 17 locations

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 10773 Tablets

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: BI 10773 Placebo
Drug: BI 10773

First Posted Date: 2013-08-16

Last Posted Date: 2014-07-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 48

Registration Number: NCT01924767

Locations: 🇩🇪
1245.2.1 Boehringer Ingelheim Investigational Site, Neuss, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy